NRC Health (NRC) stock
NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3081% above fair value
$26.56−0.08 (-0.30%)
Close on Nov 13, 2026Market cap $587.50MP/E –Yield 1.96%
NRC Health ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NRC Health's ebitda for the twelve months ending Sep 30, 2026 was $24.41M, down 29.3% year over year. For fiscal 2025 it was $30.21M, down 26.7% from the year before. Over ten years it grew 1.0% a year on average. The highest annual figure on record is $48.57M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.21M | -26.7% |
| FY2024 | Dec 31, 2024 | $41.22M | -10.3% |
| FY2023 | Dec 31, 2023 | $45.94M | -5.4% |
| FY2019 | Dec 31, 2019 | $48.57M | +19.2% |
| FY2018 | Dec 31, 2018 | $40.74M | +5.0% |
| FY2017 | Dec 31, 2017 | $38.81M | +9.6% |
| FY2016 | Dec 31, 2016 | $35.42M | +15.9% |
| FY2015 | Dec 31, 2015 | $30.56M | -4.8% |
| FY2014 | Dec 31, 2014 | $32.10M | +12.5% |
| FY2013 | Dec 31, 2013 | $28.54M | +4.1% |
| FY2012 | Dec 31, 2012 | $27.42M | +15.2% |
| FY2011 | Dec 31, 2011 | $23.80M | +28.2% |
| FY2010 | Dec 31, 2010 | $18.56M | +5.9% |
| FY2009 | Dec 31, 2009 | $17.53M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.98M | +10.5% |
| Q2 FY2026 | Jun 30, 2026 | -$1.12M | -133.5% |
| Q1 FY2026 | Mar 31, 2026 | $7.74M | -23.7% |
| Q4 FY2025 | Dec 31, 2025 | $6.81M | -38.6% |
| Q3 FY2025 | Sep 30, 2025 | $9.93M | +4.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.33M | -67.9% |
| Q1 FY2025 | Mar 31, 2025 | $10.14M | -0.7% |
| Q4 FY2024 | Dec 31, 2024 | $11.10M | -15.5% |
| Q3 FY2024 | Sep 30, 2024 | $9.53M | -17.2% |
| Q2 FY2024 | Jun 30, 2024 | $10.38M | -4.7% |
| Q1 FY2024 | Mar 31, 2024 | $10.21M | -2.0% |
| Q4 FY2023 | Dec 31, 2023 | $13.14M | +5.9% |
| Q3 FY2023 | Sep 30, 2023 | $11.51M | -10.0% |
| Q2 FY2023 | Jun 30, 2023 | $10.89M | -16.3% |
| Q1 FY2023 | Mar 31, 2023 | $10.41M | -24.9% |
| Q3 FY2022 | Sep 30, 2022 | $12.41M | +16.2% |
| Q2 FY2022 | Jun 30, 2022 | $12.79M | +1.8% |
| Q1 FY2022 | Mar 31, 2022 | $13.01M | -1.5% |
| Q3 FY2020 | Sep 30, 2020 | $13.87M | +19.0% |
| Q2 FY2020 | Jun 30, 2020 | $10.68M | -7.8% |
| Q1 FY2020 | Mar 31, 2020 | $12.57M | +3.7% |
| Q4 FY2019 | Dec 31, 2019 | $13.22M | +21.7% |
| Q3 FY2019 | Sep 30, 2019 | $11.65M | +10.4% |
| Q2 FY2019 | Jun 30, 2019 | $11.59M | +27.6% |
| Q1 FY2019 | Mar 31, 2019 | $12.12M | +18.3% |
| Q4 FY2018 | Dec 31, 2018 | $10.86M | +10.0% |
| Q3 FY2018 | Sep 30, 2018 | $10.55M | +27.9% |
| Q2 FY2018 | Jun 30, 2018 | $9.08M | -5.3% |
| Q1 FY2018 | Mar 31, 2018 | $10.24M | -7.7% |
| Q4 FY2017 | Dec 31, 2017 | $9.87M | -0.4% |
| Q3 FY2017 | Sep 30, 2017 | $8.25M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.59M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.91M | – |
See a number that looks wrong?